BDX

Becton Dickinson and Co

Add to Watchlist

Advanced Chart

172.590

-1.230(-0.710%)

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

173.799

Open

173.540

VWAP

172.69

Vol

3.36M

Mkt Cap

49.47B

Low

171.650

Amount

580.00M

EV/EBITDA(TTM)

13.38

Total Shares

289.01M

68.41B

EV/OCF(TTM)

20.53

P/S(TTM)

2.42

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

5.37B

+4%

3.299

-3.82%

5.89B

+8.39%

3.984

+4.56%

5.50B

+8.76%

3.431

-1.97%

Estimates Revision

The market is revising Downward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2025, with the revenue forecasts being adjusted by -0.08% over the past three months. During the same period, the stock price has changed by -24.45%.

Revenue Estimates for FY2025

Revise Downward

-0.08%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.99%

In Past 3 Month

Stock Price

Go Down

-24.45%

In Past 3 Month

12 Analyst Rating

19.59% Upside

Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 206.40 USD with a low forecast of 172.00 USD and a high forecast of 261.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

8 Hold

0 Sell

Moderate Buy

19.59% Upside

Current: 172.590

Low

172.00

Averages

206.40

High

261.00

19.59% Upside

Current: 172.590

Low

172.00

Averages

206.40

High

261.00

Citigroup

Joanna Wiensch

Strong Buy

Hold

Downgrades

$217 → $185

2025-05-22

Reason

Citigroup

Joanna Wiensch

Price Target

$217 → $185

2025-05-22

Downgrades

Strong Buy

Hold

Reason

Stifel

Rick Wise

Strong Buy

Maintains

$280 → $224

2025-05-02

Reason

Stifel

Rick Wise

Price Target

$280 → $224

2025-05-02

Maintains

Strong Buy

Reason

Stifel analyst Rick Wise lowered the firm's price target on Becton Dickinson to $224 from $280 and keeps a Buy rating on the shares. Q2 performance and FY25 guidance were both "more disappointing and more complicated than anticipated," the analyst tells investors. Both the Q2 underperformance and now-higher China pressures are factors in the firm's revised estimates and price target, the analyst indicated.

Piper Sandler

Jason Bednar

Buy

Hold

Downgrades

$260 → $185

2025-05-02

Reason

Piper Sandler

Jason Bednar

Price Target

$260 → $185

2025-05-02

Downgrades

Buy

Hold

Reason

Piper Sandler analyst Jason Bednar downgraded Becton Dickinson to Neutral from Overweight with a price target of $185, down from $260. The firm says its "patience has fully worn out" on the company's "checkered execution path" for organic revenue. Piper's confidence has eroded in management's demand forecasting ability. Becton's fiscal Q2 saw nearly every segment revenue line miss expectatoins on an organic growth basis, the analyst tells investors in a research note. Piper "can no longer justifiably defend" that the company's guidance is achievable.

William Blair

Brian Weinstein

Buy

Hold

Downgrades

n/a

2025-05-01

Reason

William Blair

Brian Weinstein

Price Target

n/a

2025-05-01

Downgrades

Buy

Hold

Reason

Piper Sandler

Jason Bednar

Buy

Maintains

$280 → $260

2025-04-23

Reason

Piper Sandler

Jason Bednar

Price Target

$280 → $260

2025-04-23

Maintains

Buy

Reason

Piper Sandler analyst Jason Bednar lowered the firm's price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.

Barclays

Travis Steed

Buy

Maintains

$279 → $261

2025-04-07

Reason

Barclays

Travis Steed

Price Target

$279 → $261

2025-04-07

Maintains

Buy

Reason

Barclays lowered the firm's price target on Becton Dickinson to $261 from $279 and keeps an Overweight rating on the shares. The firm updated its sum-of-the-parts analysis following reports that the company plans to separate its Bioscience and Diagnostics Solutions business. It cites a drop in peer multiples for the target cut.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 12.35, compared to its 5-year average forward P/E of 19.66. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

19.66

Current PE

12.35

Overvalued PE

22.11

Undervalued PE

17.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

15.45

Current EV/EBITDA

10.68

Overvalued EV/EBITDA

17.14

Undervalued EV/EBITDA

13.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

3.56

Current PS

2.25

Overvalued PS

3.92

Undervalued PS

3.20

Financials

Annual

Quarterly

FY2025Q2

YoY :

+4.50%

5.27B

Total Revenue

FY2025Q2

YoY :

-23.00%

646.00M

Operating Profit

FY2025Q2

YoY :

-42.64%

308.00M

Net Income after Tax

FY2025Q2

YoY :

-42.16%

1.07

EPS - Diluted

FY2025Q2

YoY :

-90.79%

35.00M

Free Cash Flow

FY2025Q2

YoY :

-6.26%

42.81

Gross Profit Margin - %

FY2025Q2

YoY :

-45.11%

5.84

Net Margin - %

FY2025Q2

YoY :

+16.41%

4.61

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

636.4K

USD

3-6

Months

3.1M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

350.4K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

536.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

803.3K

Volume

Bought

0-3

0.0

Volume

Months

3-6

298.7K

Volume

Months

6-9

0.0

Volume

Months

0-12

6.2M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

81.0K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

8.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

636.4K

USD

3-6

Months

3.1M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

350.4K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BDX News & Events

Events Timeline

2025-05-28 (ET)

2025-05-28

06:57:17

Becton Dickinson to initiat patient data registry for Rotarex Atherectomy System

2025-05-01 (ET)

2025-05-01

06:37:34

Becton Dickinson cuts FY25 adjusted EPS view to $14.06-$14.34 from $14.30-$14.60

2025-05-01

06:34:06

Becton Dickinson reports Q2 adjusted EPS $3.35, consensus $3.28

News

3.5

05-28Newsfilter

BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

3.5

05-28PRnewswire

BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

1.0

05-27PRnewswire

BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference

People Also Watch

Republic Services Inc

Canadian Natural Resources Ltd

FAQ

What is Becton Dickinson and Co (BDX) stock price today?

The current price of BDX is 172.59 USD — it has decreased -0.71 % in the last trading day.

BDX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BDX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Becton Dickinson and Co (BDX) stock price today?

What is Becton Dickinson and Co (BDX)'s business?

What is the price predicton of BDX Stock?

What is Becton Dickinson and Co (BDX)'s revenue for the last quarter?

What is Becton Dickinson and Co (BDX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Becton Dickinson and Co (BDX)'s fundamentals?

How many employees does Becton Dickinson and Co (BDX). have?

What is Becton Dickinson and Co (BDX) market cap?